Total trials
79
Active
27
Phase 3
24
Total enrollment
72,861
Pipeline matrix
Showing 36 of 36 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| SCTC21C | — | — | — | 5 | |||
| SCTB35 | — | — | — | 4 | |||
| SCTB41 | — | — | — | — | 3 | ||
| Lenalidomide | — | — | — | — | — | 2 | |
| Bortezomib | — | — | — | — | — | 2 | |
| Dexamethasone | — | — | — | — | — | 2 | |
| SCTB14 | — | — | — | — | 2 | ||
| SCTA01 | — | — | — | — | 4 | ||
| Paclitaxel | — | — | — | — | 3 | ||
| Carboplatin | — | — | — | — | — | 2 | |
| Rituximab | — | — | — | — | 2 | ||
| Cyclophosphamide | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | — | 1 | |
| Rituxumab | — | — | — | — | — | 1 | |
| Gemcitabine | — | — | — | — | — | 1 | |
| Oxaliplatin | — | — | — | — | — | 1 | |
| SCT800 prophylaxis and treatment for bleeding events | — | — | — | — | — | 1 | |
| Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell） | — | — | — | — | — | 1 | |
| Tislelizumab | — | — | — | — | — | 1 | |
| Nab-paclitaxel | — | — | — | — | — | 1 | |
| Cisplatin | — | — | — | — | — | 1 | |
| Pemetrexed | — | — | — | — | — | 1 | |
| SCT650C | — | — | — | — | 3 | ||
| docetaxel | — | — | — | 3 | |||
| SCTB39-1 | — | — | — | — | — | 1 | |
| SCTT11 | — | — | — | — | — | 1 | |
| SCTV02 | — | — | — | — | — | 1 | |
| SCTB41+SCTB39-1 | — | — | — | — | — | 1 | |
| Recombinant Herpes Zoster Vaccine (SCTV04C) Low-Dose | — | — | — | — | — | 1 | |
| Recombinant Herpes Zoster Vaccine (SCTV04C) High-Dose | — | — | — | — | — | 1 | |
| Shingrix® | — | — | — | — | — | 1 | |
| Ganwei® | — | — | — | — | — | 1 | |
| SCT520FF | — | — | — | — | — | 1 | |
| EYLEA 2 MG | — | — | — | — | — | 1 | |
| SCTB39G | — | — | — | — | — | 1 | |
| SCTB41+SCTB39G | — | — | — | — | — | 1 |
Next readouts
- 2022-01-01
- 2024-03
- 2025-08-28
- 2025-11-10
- 2026-06-24
- 2026-07-01
- 2026-09-23
- 2026-10
- 2027-03-12
- 2027-04
Top conditions
- COVID-1917
- SARS-CoV-2 Infection11
- Hemophilia A5
- Advanced Malignant Solid Tumor3
- Head and Neck Squamous Cell Carcinoma3
- Metastatic Colorectal Cancer2
- B-cell Non Hodgkin's Lymphoma2
- Esophageal Squamous Cell Carcinoma2
Frequently asked questions about Sinocelltech Ltd.
- How many clinical trials does Sinocelltech Ltd. have on ClinicalTrials.gov?
- Sinocelltech Ltd. is listed as the lead sponsor on 79 clinical trials in ClinicalTrials.gov, 27 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Sinocelltech Ltd.'s trials are in Phase 3?
- 24 of Sinocelltech Ltd.'s trials are in Phase 3, spread across 36 active drug programs.
- What therapeutic areas does Sinocelltech Ltd. focus on?
- Sinocelltech Ltd.'s most-studied conditions on ClinicalTrials.gov are COVID-19, SARS-CoV-2 Infection, Hemophilia A, Advanced Malignant Solid Tumor, Head and Neck Squamous Cell Carcinoma.
- When are Sinocelltech Ltd.'s next clinical trial readouts?
- Sinocelltech Ltd. has 10 upcoming primary-completion readouts tracked here; the soonest is “To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19”, expected around 2022-01-01.